IN8bio: Data for Gamma-Delta nsCAR-T cell therapy platform presented at AACR

IN8bio announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell, nsCAR, platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research Annual Meeting 2024 on April 9 …The new data presented at AACR included results from proprietary constructs targeting CD33 and/or CD123 for in vitro evaluation against various types of leukemia, including acute myeloid leukemia AML and chronic myeloid leukemia . The study results demonstrated notable differences between cells expressing traditional signaling CARs and those expressing the nsCAR constructs, which include a reduction in activation-induced cell death with nsCAR constructs.